Producer
SCHOTT Pharma AG & Co. KGaA
German pharmaceutical glass specialist (FRA: 1SXP; IPO September 2023 at ~€3.6B market cap); subsidiary of SCHOTT AG, which is wholly owned by the Carl Zeiss Foundation — a non-profit foundation structure that has owned SCHOTT since 1884. SCHOTT Pharma is the world's largest manufacturer of pharmaceutical primary packaging glass, holding an estimated 35-45% of the global pharmaceutical borosilicate glass tubing market from which vials, ampoules, and syringes are drawn. Type I borosilicate glass has been SCHOTT's core product since founder Otto Schott invented borosilicate glass composition in 1884, and SCHOTT has the longest continuous manufacturing history of any pharmaceutical glass maker. Key pharmaceutical glass vial production plants in Müllheim (Germany), Jena (Germany), Schweinfurt (Germany), and multiple international sites. Supplied hundreds of millions of vials for COVID-19 vaccine programs including BioNTech/Pfizer mRNA vaccines.
3
Inputs supplied
3
Goods downstream
3
Facilities
0
Stories
What they make
3 inputs SCHOTT Pharma AG & Co. KGaA supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something SCHOTT Pharma AG & Co. KGaA makes, pick one to see the full supply chain.
Where they make it
3 facilities
SCHOTT Pharma Müllheim Glass Vial Plant →
DEBaden-Württemberg · manufacturing
SCHOTT Pharma primary pharmaceutical vial production at Müllheim, Baden-Württemberg, Germany. One of SCHOTT's highest-capacity vial manufacturing sites; produces Type I borosilicate glass vials for injectable drugs including COVID-19 vaccine vials. SCHOTT Müllheim produces ready-to-use vials (Fiolax® tubing drawn elsewhere, converted here) and is a core facility for SCHOTT Pharma's European pharmaceutical glass supply. SCHOTT announced €100M capacity expansion following COVID-19 vaccine demand (2021-2023). Source: https://www.schott.com/en-us/news/press-releases/2021/schott-invests-in-vaccine-glass
SCHOTT Pharma Pune →
INMaharashtra · manufacturing
Opened March 2023 for FIOLAX amber pharmaceutical glass production to serve Asian market growth.
Schott Pharma Mainz Headquarters & Production →
DEMainz, Rhineland-Palatinate · glass_tubing_and_vials
Primary R&D and production facility. Produces borosilicate glass tubing (Fiolax) and finished primary packaging.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Pharmaceutical Glass Tubing (Type I Borosilicate)
40%Formed Packaging (Vials + Syringes + Cartridges)
55%Specialty Containers
5%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Concentration2023
SCHOTT Pharma is owned by the Carl Zeiss Foundation (Carl-Zeiss-Stiftung) — a non-profit foundation established in 1889 under a unique legal structure that makes it the sole owner of both SCHOTT AG and Carl Zeiss AG, neither of which can be sold, listed, or acquired without an act of the German legislature. The Zeiss Foundation structure means SCHOTT Pharma — the world's most important pharmaceutical glass company — is constitutionally insulated from hostile acquisition, shareholder pressure for short-term returns, and conventional M&A. While SCHOTT Pharma completed an IPO on the Frankfurt Stock Exchange in September 2023 (~25% float), majority control permanently resides with a foundation that does not distribute dividends. This ownership structure is why SCHOTT has maintained pharmaceutical glass manufacturing in Germany for 140 years when most other glass manufacturing has migrated to lower-cost countries — the foundation's mandate is long-term preservation of the business and its German employees, not profit maximization. SCHOTT is the only pharmaceutical glass manufacturer in the world whose ownership structure prevents acquisition by a foreign government, private equity, or strategic acquirer.
Wikipedia ↗Did you know2023
SCHOTT Pharma's glass cartridge products serve both the established insulin pen market AND the explosive GLP-1 drug market from the same manufacturing platform: (1) Insulin cartridges — 1.5ml and 3.0ml borosilicate glass cartridges have been used in insulin pen systems (NovoPen, KwikPen, SoloStar) since the 1980s; the global insulin-dependent diabetic population (including Type 1 and insulin-requiring Type 2) creates steady demand; (2) GLP-1 drug cartridges — the same glass cartridge format is used in semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) auto-injector pens; as GLP-1 drugs became the fastest-growing pharmaceutical category globally in 2023-2025, demand for glass cartridges surged faster than manufacturing capacity could expand; SCHOTT Pharma was named in multiple pharmaceutical supply chain analyses as a capacity constraint for GLP-1 pen cartridge supply. The glass cartridge container connecting decades of insulin delivery technology to the GLP-1 obesity revolution is the same SCHOTT Pharma borosilicate glass tube bent, formed, and filled to pharmaceutical standards. The capacity bottleneck for the world's most-demanded new drug class is a 140-year-old German pharmaceutical glass manufacturer.
SCHOTT Pharma AG & Co. KGaA ↗Origin2023
SCHOTT Pharma traces to the 1884 invention by Otto Schott of borosilicate glass — a glass composition with high silica content and boron trioxide, providing chemical resistance, thermal shock resistance, and the clarity/inertness required for pharmaceutical containers. Schott developed borosilicate specifically because existing soda-lime glass was chemically reactive with acidic pharmaceutical solutions. The 1884 borosilicate glass formula is effectively the same material used in SCHOTT Pharma vials 140 years later — the chemical composition that makes glass safe for injected drugs has not fundamentally changed since its invention. SCHOTT Pharma was separated from SCHOTT AG and listed on the Frankfurt Stock Exchange in September 2023 — an unusual IPO of a subsidiary from a company owned by a non-profit foundation (the Carl Zeiss Foundation, which also owns Carl Zeiss optics). The IPO raised approximately EUR 570 million while SCHOTT AG retained ~67%. The separately listed pharmaceutical glass subsidiary is embedded in both the COVID mRNA vaccine supply chain (hundreds of millions of vials) and the GLP-1 obesity drug supply chain (glass cartridges for Ozempic/Wegovy pens) — two of the most high-profile pharmaceutical supply chain events of the 2020s.
SCHOTT Pharma AG & Co. KGaA ↗